Odisha News, Odisha Latest news, Odisha Daily - OrissaPOST
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
No Result
View All Result
OrissaPOST - Odisha Latest news, English Daily -
No Result
View All Result

COVID-19 has lower mortality rate, but more transmissible

PNN & Agencies
Updated: March 29th, 2020, 08:10 IST
in Coronavirus, Feature
0
All 103 samples of coronavirus suspects in Odisha test negative

All 103 samples of coronavirus suspects in Odisha test negative

Share on FacebookShare on TwitterShare on WhatsAppShare on Linkedin

SARS-CoV-2, the virus that causes COVID-19 disease, is more transmissible. However, it has a lower mortality rate than its sibling, SARS-CoV, according to a new review article published this week in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology.

In humans, coronavirus causes mainly acute respiratory infections. Individuals with SARS-CoV-2 may remain asymptomatic for 2 to 14 days post-infection and some individuals are likely to transmit the virus without developing disease or symptoms.

Also Read

What we know after Jensen Huang resigns as Nvidia CEO

6 days ago

74-year-old American becomes world’s oldest wingsuit flyer

1 week ago

So far, the most promising compound for treating COVID-19 is the antiviral Remdesivir. It is currently in clinical trials for treating Ebola virus infections. Remdesivir was recently tested in a non-human primate model of MERS-CoV infection.

Prophylactic treatment 24 hours prior to inoculation prevented MERS-CoV from causing clinical disease and inhibited viral replication in lung tissues, preventing formation of lung lesions. Initiation of treatment 12 hours after virus inoculation was similarly effective.

Remdesivir has also shown effectiveness against a wide range of coronaviruses. It has already undergone safety testing in clinical trials for Ebola, thereby reducing the time that would be necessary for conducting clinical trials for SARS-CoV-2.

Nonetheless, much work needs to be done to gain a better understanding of the mechanics of SARS-CoV-2. For instance, how SARS-CoV-2 interacts with the host ACE2 receptor – by which SARS-CoV-2 gains entry into the host (whether human or animal) – might reveal how this virus overcame the species barrier between animals and humans. This could also lead to design of new antivirals.

Although coronaviruses are common in bats, no direct animal source of the epidemic has been identified to date, according to the report. “It is critical to identify the intermediate species to stop the current spread and to prevent future human SARS-related coronavirus epidemics,” the researchers wrote.

Other approaches listed in their review and article published include blocking SARS-CoV-2 from entering cells, disrupting viral replication, antivirals, vaccines and suppressing overactive immune response.

Tilarone is a broad-spectrum antiviral that may also be active against SARS-CoV-2. The synthetic small molecule is used in some countries, including Russia and neighbours, to treat several viruses, including acute respiratory viral infection, influenza and hepatitis.

Other studies suggest tilarone may be active against Middle Eastern Respiratory Syndrome (MERS-CoV); however, the studies do not meet US Food and Drug Administration (FDA) standards for safety.

The review cited more than 15 vaccine candidates being developed globally, with various approaches to their design. The authors suggest the expert opinion is that it will take approximately 12 to 18 months to get one to market.

Tags: CoronavirusCOVID-19SARS-CoV-2
ShareTweetSendShare
Suggest A Correction

Enter your email to get our daily news in your inbox.

 

OrissaPOST epaper Sunday POST OrissaPOST epaper

Click Here: Plastic Free Odisha

#MyPaperBagChallenge

Shreyanshu Bal

December 12, 2019
#MyPaperBagChallenge

Subhajyoti Mohanty

December 12, 2019
#MyPaperBagChallenge

Anasuya Sahoo

December 12, 2019
#MyPaperBagChallenge

Akriti Negi

December 12, 2019
#MyPaperBagChallenge

D Rama Rao

December 12, 2019
#MyPaperBagChallenge

Jhili Jena

December 12, 2019
#MyPaperBagChallenge

Parbati Mohanty

December 12, 2019
#MyPaperBagChallenge

Vandana Singh

December 12, 2019
#MyPaperBagChallenge

Debasis Mohanty

December 12, 2019
#MyPaperBagChallenge

Ipsita

December 12, 2019
#MyPaperBagChallenge

Nishikant Rout

December 12, 2019
#MyPaperBagChallenge

Sarmistha Nayak

December 12, 2019
#MyPaperBagChallenge

Mandakini Dakua

December 12, 2019
#MyPaperBagChallenge

Keshab Chandra Rout

December 12, 2019
#MyPaperBagChallenge

Sarfraz Ahmad

December 12, 2019
#MyPaperBagChallenge

Rajashree Manasa Mohanty

December 12, 2019
#MyPaperBagChallenge

Chinmay Kumar Routray

December 12, 2019
#MyPaperBagChallenge

Aman Kumar Barisal

December 12, 2019
#MyPaperBagChallenge

Priyasha Pradhan

December 12, 2019
#MyPaperBagChallenge

Swarit Praharaj

December 12, 2019
#MyPaperBagChallenge

Diptiranjan Biswal

December 12, 2019
#MyPaperBagChallenge

Geetanjali Patro

December 12, 2019
#MyPaperBagChallenge

Praptimayee Biswal

December 12, 2019
#MyPaperBagChallenge

Kamana Singh

December 12, 2019
#MyPaperBagChallenge

Faiza Firdous

December 12, 2019
#MyPaperBagChallenge

Tapaswini Mallick

December 12, 2019
#MyPaperBagChallenge

Anshuman Sahoo

December 12, 2019
#MyPaperBagChallenge

Tabish Maaz

December 12, 2019
#MyPaperBagChallenge

Pragyan Priyambada

December 12, 2019
#MyPaperBagChallenge

Ramakanta Sahoo

December 12, 2019

Archives

Editorial

Tech Terror

November 18, 2026

It cannot be a coincidence that when the world was still trying to come to terms with the prospect of...

Read moreDetails

More Miseries Ahead

Inflation in India
November 17, 2026

Life is getting difficult by the day for Indians with all us citizens reeling under the dual shocks of rising...

Read moreDetails

Tough Times

Press
November 16, 2026

Press freedom has, for years, been under attack almost everywhere across the globe, but the situation has never been as...

Read moreDetails

Democracy Strikes Back

Rights & Restrictions: AAKAR PATEL
November 15, 2026

By Aakar Patel Democracies correct themselves through elections. The leadership of every nation is imperfect, and the problems become especially...

Read moreDetails
  • Home
  • State
  • Metro
  • National
  • International
  • Business
  • Editorial
  • Opinion
  • Sports
  • About Us
  • Advertise
  • Contact Us
  • Jobs
Developed By Ratna Technology

© 2025 All rights Reserved by OrissaPOST

  • News in Odia
  • Orissa POST Epaper
  • Video
  • Home
  • Trending
  • Metro
  • State
  • Odisha Special
  • National
  • International
  • Sports
  • Business
  • Editorial
  • Entertainment
  • Horoscope
  • Careers
  • Feature
  • Today’s Pic
  • Opinion
  • Sci-Tech
  • About Us
  • Contact Us
  • Jobs

© 2025 All rights Reserved by OrissaPOST

    • News in Odia
    • Orissa POST Epaper
    • Video
    • Home
    • Trending
    • Metro
    • State
    • Odisha Special
    • National
    • International
    • Sports
    • Business
    • Editorial
    • Entertainment
    • Horoscope
    • Careers
    • Feature
    • Today’s Pic
    • Opinion
    • Sci-Tech
    • About Us
    • Contact Us
    • Jobs

    © 2025 All rights Reserved by OrissaPOST